Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

NCT04787042 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

316

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Solid Tumor
Melanoma
Renal Cell Carcinoma
Triple-negative Breast Cancer
Non Small Cell Lung Cancer
Squamous Cell Carcinoma of the Head and Neck
Carcinoma
MSI-High

Interventions

BIOLOGICAL: ST-067
BIOLOGICAL: Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]
BIOLOGICAL: pembrolizumab

Sponsor

Simcha IL-18, Inc.

Collaborators

[object Object]